PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS
Abstract
Authors
M. Carrasco Perez A. Ustyugova M. Rubio D. Callejo-Velasco D. Gasche N. Gonzalez-Rojas Guix